Neogen Corporation (NEOG)

NASDAQ • Healthcare

$12.19

+$0.2 (+1.8%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$11.97

Previous Close$12.19

Day Range$11.82 - $12.34

Avg. Volume (3M)4.9M

Market Cap$2.6B

52 Week Range

$5.37$14.26

Next EarningsIn 81 daysJan 14, 2027

Metrics Over Time

Where the Money Goes

Q3 2026

Revenueeverything earned$222.8M100%

Gross Profitminus cost of goods$105.5M47%

In plain terms: out of every $100 in revenue, Neogen Corporation currently loses $5.

Fundamentals & Financials

Revenue (TTM)

$883.9M

Net Income (TTM)

-$56.1M

EPS (TTM)

-$0.25

ROA (TTM)

-1.7%

Current Ratio

3.9

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+154.1%Q4 2025$0.04

+42.9%Q1 2026$0.1

+125.0%Q2 2026$0.09

+58.8%Q3 2026$0.09

+50.0%Q4 2026$0.08

Jan 14

in 81 daysQ1 2027

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Neogen Corporation

Neogen Corporation (NASDAQ: NEOG) develops and sells diagnostics and related animal-health products for the healthcare field, with operations centered on food and animal safety. The company generated $870.4 million of revenue in FY2026. Its business spans contaminant detection, sanitation verification, veterinary care, and hygiene products sold into testing and production environments worldwide.

Name

Neogen Corporation

CEO

Mikhael Nassif

Website

www.neogen.com

Industry

Healthcare

Year Founded

1981

Employees

2,636

Today's Snapshot

AI-generated

The day ended with NEOG 1.8% higher at 12.19, outperforming a weaker sector.

Trading Volume

Below 10d avg (2.7M)

2.6M

vs S&P 500 Today

Outperforming Market

+2.27%

Updated: October 23, 2026 at 20:23 UTC

Technical Indicators

5 Buy2 Neutral1 Sell

NEOG sits in a neutral technical posture as momentum indicators hover near balance and the ADX points to a weak trend, so neither side shows convincing control. The price is at or slightly above several short- and medium-term moving averages and comfortably above the 200-day average, while MACD is marginally negative and RSI is near midpoint, reflecting limited momentum. Volume on-balance is supportive, and volatility is contained at a low single-digit percent ATR, with the pivot slightly below the market. Technical takeaway: Neutral — mixed momentum and light trend strength leave the market without a clear directional bias.

All signals